.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 3,896,157

« Back to Dashboard

Details for Patent: 3,896,157

Title: Dihydo 2-naphthylacetic acid derivatives
Abstract:2-Naphthyl acetic acid derivatives and the corresponding amides, esters, hydroxamic acids and addition salts thereof, optionally substituted at the .alpha.-position on the acetic acid moiety and/or at position 6 and/or at positions 1, 4, 7 or 8 on the naphthyl ring and optionally saturated at positions 3 and 4, are anti-inflammatory, analgesic, anti-pyretic and anti-pruritic agents. A pharmaceutical method of effecting treatment of inflammation, pain, pyrexia and pruritus by the administration of naphthyl acetic acid derivatives. A pharmaceutical composition for use in the treatment of the above maladies comprising a naphthyl acetic acid derivative.
Inventor(s): Fried; John H. (Palo Alto, CA), Harrison; Ian T. (Palo Alto, CA)
Assignee: Syntex Corporation (Panama City, PM)
Filing Date:Nov 04, 1971
Application Number:05/195,878
Claims:1. A compound selected from the group consisting of 3,4-dihydro-6-fluoro-2-naphthyl-.alpha.-methylacetic acid, the alkyl esters thereof wherein the alkyl moiety has 1 to 12 carbon atoms, and the pharmaceutically acceptable addition salts thereof.

2. A compound selected from the group consisting of 3,4-dihydro-6-chloro-2-naphthyl-.alpha.-methylacetic acid, the alkyl esters thereof wherein the alkyl moiety has 1 to 12 carbon atoms, and the pharmaceutically acceptable addition salts thereof.

3. A compound selected from the group consisting of 3,4-dihydro-6-methyl-2-naphthyl-.alpha.-methylacetic acid, the alkyl esters thereof wherein the alkyl moiety has 1 to 12 carbon atoms, and the pharmaceutically acceptable addition salts thereof.

4. A compound selected from the group consisting of 3,4-dihydro-6-trifluoromethyl-2-naphthyl-.alpha.-methylacetic acid, the alkyl esters thereof wherein the alkyl moiety has 1 to 12 carbon atoms, and the pharmaceutically acceptable addition salts thereof.

5. A compound selected from the group consisting of 3,4-dihydro-6-methoxy-2-naphthyl-.alpha.-methylacetic acid, the alkyl esters thereof wherein the alkyl moiety has 1 to 12 carbon atoms, and the pharmaceutically acceptable addition salts thereof.

6. A compound selected from the group consisting of 3,4-dihydro-6-methylthio-2-naphthyl-.alpha.-methylacetic acid, the alkyl esters thereof wherein the alkyl moiety has 1 to 12 carbon atoms, and the pharmaceutically acceptable addition salts thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc